Drugs / autologous Epstein-Barr virus-specific cytotoxic T lymphocytes
autologous Epstein-Barr virus-specific cytotoxic T lymphocytes
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00690872 | Jul 2008 → Dec 2014 | head and neck cancer | National Cancer Centre, Singapore | Unknown | No outcome recorded |
| Phase 2 | NCT00005606 | Feb 2000 → Sep 2003 | leukemia, plasma cell neoplasm | Northwestern University | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | autologous Epstein-Barr virus-specific cytotoxic T lymphocytes | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00005606 ↗ |
| Modality | Cell therapy | “Autologous and allogeneic Epstein Barr virus (EBV) reactive lymphocytes are isolated from patients and siblings and tested in vitro for cytotoxic activity.” NCT00005606 ↗ |
| Route | Intravenous | “EBV-specific CTLs IV over 1-10 minutes” NCT00690872 ↗ |